PNC-28
$34.99 – $54.99Price range: $34.99 through $54.99
A p53-derived synthetic peptide combining the MDM2-binding domain of p53 (residues 17-26) with a membrane-penetrating sequence, researched for selective cancer cell necrosis via HDM2-dependent pore formation.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.
Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Store lyophilized at -20°C. Protect from light. Limited stability in serum due to proteolysis.
PNC-28 is a synthetic peptide derived from the MDM2-binding domain of the tumor suppressor protein p53 (residues 17-26: ETFSDLWKLL), linked to a membrane-penetrating sequence (penetratin/Antennapedia homeodomain sequence) at its C-terminus. The penetratin sequence enables cellular uptake, while the p53-derived domain targets HDM2 (human MDM2) protein, which is aberrantly expressed on the plasma membrane surface of cancer cells but not normal cells. Upon binding to membrane-expressed HDM2, PNC-28 induces formation of transmembrane pores leading to rapid tumor cell necrosis (within minutes to hours) rather than the slower process of apoptosis. This mechanism is selective: normal cells lack surface HDM2 expression and are therefore resistant to PNC-28 toxicity. Research has demonstrated PNC-28 activity against cancer cells from over 20 different human epithelial cancer lines including pancreatic, colon, lung, breast, and ovarian cancers in vitro, and inhibition of pancreatic cancer growth in vivo. The related peptide PNC-27 uses the same mechanism. PNC-28 has also been studied in combination with chemotherapy and as a model for peptide-based cancer immunotherapy. No human clinical trials have been completed.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-B6374 COA-Y2ME-A7WT-9 | 04 Aug 2026 | 98.31 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
Binds HDM2 (MDM2) expressed on cancer cell plasma membranes; forms transmembrane pores causing rapid necrotic cell lysis; selective for HDM2-expressing cancer cells; does not affect normal cells lacking surface HDM2; mechanism is pore formation rather than apoptotic pathway activation.
Primary uses / indications
Pancreatic cancer research, HDM2-targeted cancer therapy research, epithelial cancer research, anti-cancer peptide development, p53 pathway research
Typical dosage (reported)
Preclinical: variable doses in cancer models; no established human dose
Cycle duration (reported)
Research protocols only; no clinical dosing established
Administration route
Subcutaneous injection, Intratumoral injection (preclinical)
Side effects (reported)
No human safety data. Preclinical: selective for cancer cells in vitro. Theoretical: inflammatory response from necrotic tumor lysis (tumor lysis syndrome risk).
Contraindications
Active autoimmune conditions; theoretical concern for healthy tissue expressing any MDM2; pregnancy/breastfeeding
Drug interactions
Potential synergy with MDM2 antagonists (nutlin-3); theoretical interference with p53-MDM2 interaction drugs; caution with immunosuppressants
Identity
| Full name / brand names | PNC-28 / p53-Derived Anticancer Peptide / p53(17-26)-Penetratin |
|---|---|
| Category | Anti-Aging & Longevity |
| Subcategory | Anti-Cancer Research Peptide |
| Origin / source | Synthetic; first reported by Kanovsky et al., Proc Natl Acad Sci USA 2001;98(22):12438-12443, from the laboratories of Matthew R. Pincus and Josef Michl (Harbor Veterans Affairs Medical Center and SUNY Downstate Medical Center, Brooklyn, New York), designed from conformational analysis of the p53 MDM2-binding domain |
| Year discovered | 2001 |
Chemistry
| Amino acid sequence | ETFSDLWKLLKKWKMRRNQFWVKVQRG (27 residues: p53 residues 17-26, ETFSDLWKLL, fused at its carboxyl terminus to the membrane-residency/penetratin leader KKWKMRRNQFWVKVQRG) |
|---|---|
| Molecular formula | Not established |
| Molecular weight | Not established |
| CAS number | 392661-17-5 |
| PubChem CID | Not assigned (MedChemExpress product) |
| UniProt ID | P04637 (TP53/p53) |
| Purity standard | ≥98% |
Pharmacokinetics
| Half-life | Short (minutes; serum proteolysis) |
|---|---|
| Bioavailability | Injectable: moderate in vivo stability; rapid serum degradation |
Regulatory & research status
| FDA status | Not FDA-approved. Research use only. |
|---|---|
| Prescription required | Research use only |
| Research status | Preclinical research; in vitro and animal models; no completed human clinical trials |
| Clinical trials | No registered human clinical trials |
References
Kanovsky M, Raffo A, Drew L, et al., "Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells", Proc Natl Acad Sci USA, 2001;98(22):12438-12443, DOI: 10.1073/pnas.211280698; Michl J, Scharf B, Schmidt A, et al., "PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo", International Journal of Cancer, 2006;119(7):1577-1585, DOI: 10.1002/ijc.22029; Pincus MR et al., "Anticancer peptide PNC-27 adopts an HDM2-binding conformation and kills cancer cells by binding to HDM2 in their membranes", PNAS, 2010, DOI: 10.1073/pnas.0909364107
Frequently asked questions
What is PNC-28?
How does PNC-28 work?
What PNC-28 dosage is used in research?
What is the half-life of PNC-28?
How should PNC-28 be stored and reconstituted?
What purity is NHOV's PNC-28?
Is PNC-28 approved for human use?
Related products
NAD+
Cellular coenzyme and sirtuin cofactor studied in DNA repair and aging research.
$39.99 – $61.99Price range: $39.99 through $61.99Epithalon
Synthetic tetrapeptide studied as a telomerase activator in longevity research.
$21.99 – $35.99Price range: $21.99 through $35.99MOTS-c
Mitochondria-derived peptide studied for AMPK activation and metabolic research.
$36.99 – $47.99Price range: $36.99 through $47.99SS-31
Mitochondria-targeted peptide that binds cardiolipin in the inner membrane.
$29.99 – $49.99Price range: $29.99 through $49.99FOXO4-DRI
Senolytic D-amino acid peptide that disrupts the FOXO4-p53 interaction.
$87.99 – $166.99Price range: $87.99 through $166.99Humanin
Mitochondria-derived peptide studied for BAX binding and cytoprotection.
$73.99 – $117.99Price range: $73.99 through $117.99Livagen
Synthetic bioregulatory tetrapeptide studied in liver and chromatin research.
$20.99 – $32.99Price range: $20.99 through $32.99
Actovegin
Deproteinized calf blood ultrafiltrate studied in cellular glucose uptake research.
$34.99 – $54.99Price range: $34.99 through $54.99









Reviews
Clear filtersThere are no reviews yet.